161314-17-6,MFCD02179370
Catalog No.:AA00ATIK

161314-17-6 | AcetaMide, N-hydroxy-2-[[(4-Methoxyphenyl)sulfonyl](2-Methylpropyl)aMino]-

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
≥99%
in stock  
$53.00   $37.00
- +
5mg
≥99%
in stock  
$92.00   $64.00
- +
25mg
≥99%
in stock  
$380.00   $266.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00ATIK
Chemical Name:
AcetaMide, N-hydroxy-2-[[(4-Methoxyphenyl)sulfonyl](2-Methylpropyl)aMino]-
CAS Number:
161314-17-6
Molecular Formula:
C13H20N2O5S
Molecular Weight:
316.3733
MDL Number:
MFCD02179370
SMILES:
ONC(=O)CN(S(=O)(=O)c1ccc(cc1)OC)CC(C)C
Properties
Computed Properties
 
Complexity:
424  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
21  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
7  
XLogP3:
1.2  

Literature

Title: PTX3 controls activation of matrix metalloproteinase 1 and apoptosis in conjunctivochalasis fibroblasts.

Journal: Investigative ophthalmology & visual science 20120601

Title: Spinal matrix metalloproteinase 3 mediates inflammatory hyperalgesia via a tumor necrosis factor-dependent mechanism.

Journal: Neuroscience 20120103

Title: Mesenchymal stem cells support dorsal root ganglion neurons survival by inhibiting the metalloproteinase pathway.

Journal: Neuroscience 20110113

Title: Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).

Journal: European journal of medicinal chemistry 20101201

Title: On-line chromatographic screening of matrix metalloproteinase inhibitors using immobilized MMP-9 enzyme reactor.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100701

Title: Matrix metalloproteinase-3 in articular cartilage is upregulated by joint immobilization and suppressed by passive joint motion.

Journal: Matrix biology : journal of the International Society for Matrix Biology 20100601

Title: Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.

Journal: Journal of medicinal chemistry 20100325

Title: Matrix metalloproteinase-3 accelerates wound healing following dental pulp injury.

Journal: The American journal of pathology 20091101

Title: Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.

Journal: Carcinogenesis 20090301

Title: Matrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors.

Journal: Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 20071101

Title: Catalytic domain of MMP20 (Enamelysin) - the NMR structure of a new matrix metalloproteinase.

Journal: FEBS letters 20071002

Title: Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.

Journal: Bioorganic & medicinal chemistry 20070315

Title: Activity of anchored human matrix metalloproteinase-1 catalytic domain on Au (111) surfaces monitored by ESI-MS.

Journal: Journal of mass spectrometry : JMS 20051201

Title: New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).

Journal: Bioorganic & medicinal chemistry 20040501

Title: Crystal structure of the catalytic domain of human matrix metalloproteinase 10.

Journal: Journal of molecular biology 20040220

Title: Inhibition of matrix metalloproteinases prevents the synthesis of insulin-like growth factor binding protein-1 during decidualization in the baboon.

Journal: Endocrinology 20031201

Title: Screening of stress enhancer based on analysis of gene expression profiles: enhancement of hyperthermia-induced tumor necrosis by an MMP-3 inhibitor.

Journal: Cancer science 20030701

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 161314-17-6
Tags:161314-17-6 Molecular Formula|161314-17-6 MDL|161314-17-6 SMILES|161314-17-6 AcetaMide, N-hydroxy-2-[[(4-Methoxyphenyl)sulfonyl](2-Methylpropyl)aMino]-
Catalog No.: AA00ATIK
161314-17-6,MFCD02179370
161314-17-6 | AcetaMide, N-hydroxy-2-[[(4-Methoxyphenyl)sulfonyl](2-Methylpropyl)aMino]-
Pack Size: 1mg
Purity: ≥99%
in stock
$53.00 $37.00
Pack Size: 5mg
Purity: ≥99%
in stock
$92.00 $64.00
Pack Size: 25mg
Purity: ≥99%
in stock
$380.00 $266.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA00ATIK
Chemical Name: AcetaMide, N-hydroxy-2-[[(4-Methoxyphenyl)sulfonyl](2-Methylpropyl)aMino]-
CAS Number: 161314-17-6
Molecular Formula: C13H20N2O5S
Molecular Weight: 316.3733
MDL Number: MFCD02179370
SMILES: ONC(=O)CN(S(=O)(=O)c1ccc(cc1)OC)CC(C)C
Properties
Complexity: 424  
Covalently-Bonded Unit Count: 1  
Heavy Atom Count: 21  
Hydrogen Bond Acceptor Count: 6  
Hydrogen Bond Donor Count: 2  
Rotatable Bond Count: 7  
XLogP3: 1.2  
Literature fold

Title: PTX3 controls activation of matrix metalloproteinase 1 and apoptosis in conjunctivochalasis fibroblasts.

Journal: Investigative ophthalmology & visual science20120601

Title: Spinal matrix metalloproteinase 3 mediates inflammatory hyperalgesia via a tumor necrosis factor-dependent mechanism.

Journal: Neuroscience20120103

Title: Mesenchymal stem cells support dorsal root ganglion neurons survival by inhibiting the metalloproteinase pathway.

Journal: Neuroscience20110113

Title: Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).

Journal: European journal of medicinal chemistry20101201

Title: On-line chromatographic screening of matrix metalloproteinase inhibitors using immobilized MMP-9 enzyme reactor.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20100701

Title: Matrix metalloproteinase-3 in articular cartilage is upregulated by joint immobilization and suppressed by passive joint motion.

Journal: Matrix biology : journal of the International Society for Matrix Biology20100601

Title: Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.

Journal: Journal of medicinal chemistry20100325

Title: Matrix metalloproteinase-3 accelerates wound healing following dental pulp injury.

Journal: The American journal of pathology20091101

Title: Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.

Journal: Carcinogenesis20090301

Title: Matrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors.

Journal: Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry20071101

Title: Catalytic domain of MMP20 (Enamelysin) - the NMR structure of a new matrix metalloproteinase.

Journal: FEBS letters20071002

Title: Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.

Journal: Bioorganic & medicinal chemistry20070315

Title: Activity of anchored human matrix metalloproteinase-1 catalytic domain on Au (111) surfaces monitored by ESI-MS.

Journal: Journal of mass spectrometry : JMS20051201

Title: New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).

Journal: Bioorganic & medicinal chemistry20040501

Title: Crystal structure of the catalytic domain of human matrix metalloproteinase 10.

Journal: Journal of molecular biology20040220

Title: Inhibition of matrix metalloproteinases prevents the synthesis of insulin-like growth factor binding protein-1 during decidualization in the baboon.

Journal: Endocrinology20031201

Title: Screening of stress enhancer based on analysis of gene expression profiles: enhancement of hyperthermia-induced tumor necrosis by an MMP-3 inhibitor.

Journal: Cancer science20030701

Building Blocks More >
180716-28-3
180716-28-3
5-BENZOXAZOLOL
AA00AVA6 | MFCD11110248
19165-06-1
19165-06-1
2-deoxy-L-fucose
AA00AYH0 | MFCD29959598
169212-84-4
169212-84-4
1H-Benzotriazole,4-methyl-1-(1-methylethyl)-(9CI)
AA00B189 | MFCD01249183
1657-28-9
1657-28-9
3-Oxo-N-(pyridin-2-yl)butanamide
AA00B47O | MFCD00023427
18382-80-4
18382-80-4
Pyrimidine, 4,6-difluoro-2-methyl- (8CI,9CI)
AA00B6DK | MFCD18449394
161315-14-6
161315-14-6
Methyl 4-aminotetrahydro-2H-thiopyran-4-carboxylate hydrochloride
AA00B9DB | MFCD09608000
18149-16-1
18149-16-1
2-(3-methoxy-4-methylphenyl)ethanamine
AA00BBE0 | MFCD06212748
269066-08-2
269066-08-2
Fmoc-Asp(ODMAB)-OH
AA00BBME | MFCD00797875
260969-08-2
260969-08-2
([4-(Bromomethyl)phenyl]sulfonyl)(4-fluorophenyl)amine
AA00BBSH | MFCD00169942
26103-38-8
26103-38-8
N-METHYLFORM-D1-AMIDE
AA00BC1B | MFCD00958296
Submit
© 2017 AA BLOCKS, INC. All rights reserved.